Overview

Ulcer Prevention II

Status:
Completed

Trial end date:
2003-03-01

Target enrollment:

Participant gender:

Summary

Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the prevention of these gastric ulcers, in patients deemed to be at risk, with either esomeprazole 40 mg once daily; esomeprazole 20 mg once daily.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Esomeprazole